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Background. The economics of universal antenatal human immunodeficiency virus (HIV) screening should
be explored if mother-to-child transmission of HIV occurs, the health-service infrastructure for universal screening
exists, and optimal risk-reducing treatments can be supplied.
Methods. We evaluated a hypothetical cohort of the antenatal population of Australia during 2001–2002, to
examine whether universal antenatal HIV screening is cost-effective in this setting. A quasi-societal perspective
was adopted, secondary data sources were used, and sensitivity analyses were undertaken. Costs and benefits
incurred in the future were discounted to their present value.
Results. The intervention would be cost-effective if the prevalence of undiagnosed HIV in the currently
unscreened Australian antenatal population was0.004372%.We predict 6.95 new diagnoses of HIV, 1.73 infections
avoided, and 46.97 discounted-life-years gained. Applying favorable and unfavorable values for key variables suggests
that the prevalence at which the intervention would be cost-effective is 0.0016%–0.0106%.
Conclusions. Universal antenatal HIV screening would be cost-effective at a very low prevalence and would
generate net benefits under many scenarios; accurate statistics on the true prevalence of HIV in the currently
unscreened antenatal population are required.
Previous studies of the cost-effectiveness of universal
antenatal HIV screening in high-income countries have
reported or assumed a prevalence of disease of 10.01%
(1 case/10,000 population) in the target population [1–
5]. All have supported a policy of universal screening.
The economics of universal antenatal HIV screening
have not yet been evaluated in high-income settings,
where the prevalence is perceived to be very low but
where cases of mother-to-child transmission still occur.
Australia is a good example.
In 1991, Garland and Kliman [6] argued that uni-
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versal screening was not appropriate, because of small
numbers of cases of HIV in the antenatal population.
However, information published in 2003 [7] indicates
that 71 cases of mother-to-child transmission of HIV
occurred between 1982 and 2002, primarily among
women whose HIV infection was diagnosed postnatally
[7]. Also, very effective interventions are now available
to reduce the risk of mother-to-child transmission for
women whose HIV infection was diagnosed antenatally
[8–11]. In Australia, the use of interventions in women
whose HIV infection was diagnosed antenatally has
been associated with a substantially lower risk of HIV
transmission, compared with women whose HIV in-
fection was diagnosed postnatally [9].
Although current antenatal HIV screening practice
varies across the states and territories in Australia, the
national policy is that HIV testing should be conducted
if requested by the woman or if an increased risk is
identified [12], although what constitutes this risk is
undefined. Of those women currently screened, 89 with
perinatally exposed children were newly diagnosed with
HIV infection in Australia between 1998 and 2002
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[7]. Exposure to HIV was attributed to heterosexual contact in
a high-prevalence country or to heterosexual contact with a part-
ner from a high-prevalence country for 43% of the women, to
injection-drug use or heterosexual contact with an injection-drug
user for 16% of the women, and to heterosexual contact with
other partners at risk of HIV infection for 37% of the women.
Exposure to HIV was attributed to receipt of blood in 1% of the
women and remained undetermined in 3% of the women. A
total of 52 women with perinatally exposed children were newly
diagnosed with HIV infection during 2001–2002, giving a rate
of 10.5 perinatal HIV exposures/100,000 live births [7].
With an estimated 67% of antenatal women in Australia
having undetermined HIV status at the time of delivery in 1999
[13], there have been calls to revisit the debate over a policy
of universal antenatal HIV screening [14, 15]. A universal
screening program would identify previously undiagnosed cases
of HIV infection among pregnant women in Australia. Women
known to have HIV infection during pregnancy would be of-
fered antiretroviral therapy, elective caesarean delivery, if ap-
propriate, and be supported in a decision to not breast-feed
their children. The benefits of the screening program would be
avoided cases of HIV infection among exposed children, who
would enjoy a normal life expectancy. In addition, the women
and the small number of children who acquire HIV infection
perinatally, despite optimal treatment, would gain an increase
in quantity and quality of life, due to earlier diagnosis and
onset of treatment. These benefits should be considered against
the additional cost incurred from a universal screening program
[15]. The rights of the women who choose not to consent to
testing and of the women who test positive but do not wish
to receive treatment must be taken into account. An effective
and appropriate policy is required for these scenarios.
Although universal antenatal HIV screening is advocated in
a number of high-income countries on the grounds of eco-
nomic efficiency [1–5], there has been no evaluation of whether
this policy remains cost-effective in a setting of very low prev-
alence. We examine the data for Australia, where prevalence is
perceived to be very low, and develop a model of the incre-
mental cost-effectiveness of universal screening of the antenatal
population of Australia, compared with the current practice.
METHODS
Overview of the model. The predicted incremental costs of
universal screening are estimated and compared with the pre-
dicted incremental benefits. We adopt a quasi-societal per-
spective by including costs and benefits to the state-funded
health-care sector and a valuation of a life-year gained that
reflects the preferences of individuals in the community [16].
We assume that the intervention is cost-effective if the incre-
mental cost is less than or equal to the monetary valuation of
incremental benefits. The values for variables used in the model
are included in table 1. The model is evaluated for a hypo-
thetical 12-month cohort of pregnant women and includes all
future costs and benefits, which are discounted in-line with
recent debate and recommendations [38–43]. Uncertainty is
assessed by univariate sensitivity analyses. All values for cost
variables are reported in Australian dollars and reflect 2001–
2002 prices. The average exchange rates for Au$1 during this
time period were US$0.54, i0.60, £0.37, and NZ$1.25 [44].
Estimation of incremental screening and treatment costs.
We assume that antenatal HIV screening would be universally
recommended and conducted, with informed consent, by mid-
wives, obstetricians, and general practitioners. To achieve high
uptake and informed consent, we envisage the need to invest in
the continuing professional education of these health-care pro-
fessionals [45]. We assume that a proportion of women are al-
ready subject to HIV testing and, therefore, exclude the screening
and treatment costs for this group.
At the first contact with a health-care professional, every
pregnant woman would be supplied with an information packet
about the risks of HIV infection and the advantages and dis-
advantages of the proposed universal screening program. They
would also have an opportunity to discuss any concerns with
the relevant health-care professional. An HIV antibody test
would be performed for all those who consent, and the sample
would be processed by 1 of the 52 authorized and publicly
funded laboratories in Australia [46]. On the basis of an as-
sumption that all the additional testing is shared evenly between
these laboratories, workload would increase by 55 tests/week/
laboratory. This does not suggest the need to invest in extra
capital or labor. The unit cost of an ELISA that we include in
the baseline model reflects this assumption.
Women with a positive result at screening would need 2
further antibody tests and a Western blot test, for confirmation
of HIV infection, and women with true-positive results would
require additional posttest counseling. A proportion of women
with confirmed HIV infection would choose to terminate the
pregnancy. Those who continue would be offered antiretroviral
therapy under the guidance of their physician. We assume that
the women would attend regular outpatient appointments and
that the 076 treatment strategy would be followed but would
be modified to include combivir and nelfinavir for 12 weeks,
in-line with Australian guidelines for optimal treatment [47].
All women would be offered antiretroviral therapy during
labor, and some proportion would deliver by elective caesarean
delivery. During the first 6 weeks after delivery, the infant would
receive antiretroviral therapy and would attend outpatient ap-
pointments. At 6 weeks, pneumocystis prophylaxis would com-
mence and continue until at least 2 negative polymerase chain
reaction results were obtained, but the outpatient appointments
and associated diagnostic tests would continue for 12 months.
The costs of the antiretroviral therapy and other health-care
Table 1. Values used for variables included in cost-effectiveness model.
Variable
Baseline values
(unfavorable; favorable) Source
To determine epidemiological parameters
Antenatal population currently tested (without universal screening
program), %
33 (36; 30) [13]
Proportion of unscreened antenatal population who accept universal
screening, %
95 (70; 100) [59, 66–72, 75]
False-positive rate, % 0.10 (0.05; 0.2) E. Dax, personal communication
Termination-of-pregnancy rate after new diagnoses identified by screening, % 4 (10; 0) P. Tookey, personal communication
HIV-positive women who deliver by caesarean section, % 40 (21; 50) [9]a
Incidence of transmission without treatment, % 28 (21.1; 34.3) [8, 57]
Incidence of transmission with treatment, % 2 (4; 0) [8, 11, 17–21]
No. of live births per year 249,595 (244,603; 254,587) [22]
Gain in life-years (discounted) for an avoided case of HIV, years 22.99 (12.19; 29.99) [1, 35, 36]b
Gain in life years due to early treatment (discounted) for newborns, years 1.27 (0.35; 3.70) [1]
Gain in life years due to early treatment (discounted) for pregnant
women, years
1 (0; 1.97) [5]
To determine cost and benefit parameters
Pretest counseling, min 7.5 (40; 1) [73, 74, 23]
Posttest counselling for true-positive result, min 30 (60; 10) J. Murray, personal communication
Time to first true-negative result, min 2 (3;1) J. Murray, personal communication
No. of obstetricians 1100 [24]
No. of practicing midwives 13,674 [25]
No. of general practitioners 20,966 [24]
Lifetime costs for HIV-positive infant, Au$ 55,511 (41,633; 69,389) [26, 64]c
Investment in education for each HCP that may perform screening,d Au$ 10 (80; 0) Gorton C. 2003, personal communication;
Lambert S. 2002, personal communication
Unit cost, Au$
HIV antibody test 4.50 (13.05; 3) [27], P. Robertson, personal communication
Western blot confirmation 110 (132; 88) [28]
Outpatient consultation with doctor, per h 169 (203; 135) [29]
Nelfinavir tablet 1.69 [30]
Combivir tablet 10 [30]
T cell test 63 (76; 51) [28]
CMV antibody test 18 (21; 14) [28]
Termination of pregnancy 2565 (3078; 2052) [31]
Virus load determination 176 (211; 141) [28]
Caesarean delivery procedure 7454 (8945; 5963) [31]
Full blood count 10 (12; 8) [28]
Antenatal care giver,e per h 24.72 (29.67; 19.78)
Annual incremental treatment costs for all perinatally exposed infants,f Au$ 11,181 (13,417; 8945)
Incremental treatment costs of HIV-pregnant women due to early
diagnosis,f,g Au$
18,222 (24,138; 12,306)
Twice the median per capita annual income, Au$ 39,000 [16, 48]
Discount rates used
Costs, % 3 (2; 5) [32, 33]
Benefits, % 3 (5; 0) [1, 2, 41, 32, 34]
NOTE. CMV, cytomegalovirus; HCP, health-care professional (includes all midwives, general practitioners, and obstetricians).
a Indicates a caesarean delivery rate of 21%; however, currently unpublished data by the National Centre in HIV Epidemiology and Clinical Research indicate
a rate of 40%.
b Assuming for baseline (HIV negative, 79 years; HIV positive, 10 years), unfavorable (HIV negative, 71 years; HIV positive, 26 years), and favorable (HIV
negative, 87 years; HIV positive, 6 years) values.
c The original data were published in 1996 and have been adjusted to 2002 prices by use of data produced by the Australian Bureau of Statistics.
d For baseline, we assume that an educational CD-ROM developed by the Australasian Society for HIV Medicine and a brochure including policies and guidelines
is sent to every HCP involved in screening. For the favorable value, we assume zero investment; for the unfavorable value, we assume baseline values and that
every HCP attends a 2-day course on HIV and screening practice.
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e Each of the state and territory nursing federations was contacted by telephone, and the wage rates for midwives were obtained; the mean of the values
obtained are used in the model.
f Assuming an outpatient visit, T cell subset, and virus load test every 2 months, plus ongoing therapy with zidovudine.
g Assuming for baseline that the mother would have been diagnosed 19 months after delivery, regardless of universal screening, and at 12 months for favorable
and at 24 months for unfavorable values [37].
services supplied to the mother would be counted up to a point
at which they would have been diagnosed through voluntary
testing in other settings, regardless of the universal screening
program. To obtain the net cost of universal screening, the cost
savings from an avoided case of HIV infection—the lifetime
costs of treatment for a child born with HIV—are deducted
from the screening and treatment costs.
Estimation of incremental benefits. We assume that only a
proportion of all currently unscreened pregnant women would
consent. To predict the number of true- and false-positive results,
a range of values for HIV prevalence (0%–0.02%) and a rate of
false-positive results were applied. The frequency of HIV infec-
tion avoided among the children born to the women diagnosed
by universal screening was estimated by comparing the rate of
HIV transmission with treatment with the rate of HIV trans-
mission without treatment. The total life-years gained reflect the
increased life expectancy for the infants in whom HIV infection
was avoided, because of the earlier onset of treatment, the gain
in life expectancy for the infants who still contract HIV despite
optimal interventions, and the gain in life expectancy for HIV-
positive mothers. Each life-year gained was assigned a value of
twice the median per capita annual income [48] (Au$39,000), a
figure shown in a theoretical model to result in efficient alloca-
tion of resources [16]. We therefore assume that the interven-
tion is cost-effective if the cost per life-year gained (CPLYG)
is Au$39,000. This approach was preferred to the often arbi-
trary financial valuations of an incremental life-year that appear
throughout the literature [16]. It was also assumed that treatment
with antiretroviral drugs causes no adverse effects to the health
of uninfected infants [49–52].
Data sources and assumptions. All values used for the
variables included in the model are included in table 1. The
favorable and unfavorable values included for each variable
allow the model to be evaluated for alternate scenarios.
RESULTS
The results of costs and benefits for a range of prevalences are
included in table 2. The relationship between the true preva-
lence of HIV in the currently unscreened antenatal population
and the CPLYG from a universal screening program is illus-
trated in figure 1.
In the base case, the intervention would be cost-effective if
the prevalence of HIV among the currently unscreened ante-
natal population was 0.004372% (1 case/22,872 population).
Under this scenario, 6.95 new diagnoses/year would be made,
with a gain of 46.97 discounted-life-years. Valuing each life-
year gained at Au$39,000 suggests incremental benefits of
Au$1,831,963 are achieved for an identical change in cost.
At this prevalence, the incremental costs of the program
comprise $1,408,000 (73%) for pretest counselling and ELISA,
$357,000 (18%) for training health-care professionals, $16,000
(1%) for sending information to women, and $147,000 (8%)
for treatments for women and infants. These costs are offset
by savings of $96,000 due to avoided HIV treatments, which
represent 5% of the incremental costs.
The prevalence of 0.004372% is, therefore, the switching
point for cost-effectiveness. Universal screening would not be
cost-effective at lower prevalences, and net benefits would ac-
crue at any prevalence 10.004372%.
Sensitivity analysis. The CPLYG changed by 15% if fa-
vorable or unfavorable values were applied to 10 of the 35
variables included in the model; the results of this are included
in table 3. These results illustrate the minimum prevalence
among the currently unscreened antenatal population at which
universal screening would be cost-effective if the favorable or
unfavorable values were applied. For example, if the unfavor-
able value for the proportion of women who accept screening
is applied to the model, then the minimum prevalence at which
the intervention is cost-effective increases from 0.004372% to
0.006%. Also, when benefits are discounted at all rates between
and including 0% and 5%, the minimum prevalence for cost-
effectiveness is 0.0015% at discount rate 0%, 0.0023% at dis-
count rate 1%, 0.0032% at discount rate 2%, 0.0044% at dis-
count rate 3%, 0.0057% at discount rate 4%, and 0.0071% at
discount rate 5%.
DISCUSSION
With baseline values for all variables, we find a policy of cost-
effectiveness of universal screening if the prevalence among the
currently unscreened antenatal population is 0.004372% (1
case/22,872 population). Net benefits accrue at higher preva-
lences. We modelled a number of scenarios where favorable
and unfavorable values were applied to the most-influential
variables in the model. The minimum prevalence at which
universal screening was cost-effective, for the best-case scenario,
was 0.0016% (1 case/62,500 population) and, for the worst-
case scenario, was 0.0106% (1 case/9434 population). We,
therefore, have demonstrated that universal screening is cost-
effective in a setting of very low prevalence.
There was uncertainty with regard to the values for the ep-
idemiological and economic parameters. Data on the preva-
lence of HIV infection among the antenatal population of Aus-
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Table 2. Summary of results from a model of the cost-effectiveness of universal antenatal HIV screening in Australia, compared
with the current practice.
Prevalence,a % ND, no. IA, no. LYG,b no.
Benefits,c
Au$
Costs,d
Au$
Net benefits,e
Au$
Cost/ND,
Au$
Cost/IA,
Au$
Cost/LYG,
Au$
0.0010 1.59 0.40 10.74 419,009 1,792,434 1,373,425 1,128,259 4,520,269 166,834
0.0020 3.18 0.79 21.49 838,017 1,804,156 966,139 567,819 2,274,915 83,963
0.0030 4.77 1.19 32.23 1,257,026 1,815,878 558,852 381,005 1,526,464 56,339
0.0040 6.35 1.59 42.98 1,676,035 1,827,601 151,566 287,599 1,152,239 42,527
0.004372f 6.95 1.73 46.97 1,831,963 1,831,963 … 263,748 1,056,682 39,000
0.0050 7.94 1.98 53.72 2,095,043 1,839,323 255,721 231,555 927,703 34,240
0.0060 9.53 2.38 64.46 2,514,052 1,851,045 663,007 194,192 778,013 28,715
0.0070 11.12 2.78 75.21 2,933,061 1,862,767 1,070,293 167,504 671,091 24,769
0.0080 12.71 3.17 85.95 3,352,069 1,874,490 1,477,580 147,489 590,900 21,809
0.0090 14.30 3.57 96.69 3,771,078 1,886,212 1,884,866 131,921 528,529 19,507
0.0100 15.89 3.97 107.44 4,190,087 1,897,934 2,292,153 119,467 478,633 17,665
0.0110 17.48 4.36 118.18 4,609,095 1,909,656 2,699,439 109,277 437,808 16,159
0.0120 19.06 4.76 128.93 5,028,104 1,921,379 3,106,726 100,785 403,787 14,903
0.0130 20.65 5.15 139.67 5,447,113 1,933,101 3,514,012 93,600 375,001 13,841
0.0140 22.24 5.55 150.41 5,866,122 1,944,823 3,921,298 87,442 350,327 12,930
0.0150 23.83 5.95 161.16 6,285,130 1,956,545 4,328,585 82,104 328,942 12,141
0.0160 25.42 6.34 171.90 6,704,139 1,968,268 4,735,871 77,434 310,231 11,450
0.0170 27.01 6.74 182.64 7,123,148 1,979,990 5,143,158 73,313 293,721 10,841
0.0180 28.60 7.14 193.39 7,542,156 1,991,712 5,550,444 69,650 279,046 10,299
0.0190 30.18 7.53 204.13 7,961,165 2,003,434 5,957,731 66,372 265,915 9814
0.0200 31.77 7.93 214.88 8,380,174 2,015,157 6,365,017 63,423 254,097 9378
NOTE. IA, infection avoided; LYG, life-years gained; ND, new diagnosis.
a Prevalence of undiagnosed HIV in the currently unscreened antenatal population.
b In the baseline analysis, all life-years are discounted to a present value by use of a 3% rate.
c Incremental benefits associated with universal screening are based on the decision rule that a life-year gained is valued at twice the median per capita annual
income [16].
d Incremental costs associated with universal screening.
e Incremental benefit minus incremental cost equals the incremental net benefits associated with universal screening.
f Lowest prevalence at which the intervention is cost-effective (the break-even point at which incremental benefits equal incremental costs), if all variables
are set to baseline values.
tralia are scarce. In 1989, no cases were detected from 10,217
newborns screened in the New South Wales metropolitan areas,
indicating a prevalence of 0% (99% confidence interval, 0%–
0.045%) among child-bearing women [53]. Anonymous sur-
veys conducted by Chew et al. [54] of 2208 women tested in
public antenatal clinics during 1989–1990 and of 2329 women
tested during 1991–1992 found 1 positive result for each survey,
indicating prevalences of 0.045% and 0.043%, respectively. In
1996, Law et al. [55] used back-projection to estimate HIV
prevalence among pregnant women in Australia and found that,
for the period of 1983–1985, the prevalence was 0.003% (1
case/33,000 population), with a range of 0.002%–0.007% (1
case/50,000 population to 1 case/14,286 population), and, for
the period of 1992–1994, the prevalence was 0.009% (1 case/
11,111 population), with a range of 0.005%–0.02% (1 case/
20,000 population to 1 case/5000 population). Data obtained
in 1999 by Spencer et al. [13] from a survey of a randomly
selected sample of 257 private obstetricians, 606 general prac-
titioners, and 132 public hospitals indicated a prevalence of
0.023% (1 case/4348 population) among pregnant women in
Australia [13]. Although those currently tested and, therefore,
included in this survey may be considered a high-risk popu-
lation, the reported prevalence of 0.023% (1 case/4348 popu-
lation) easily exceeds the threshold for cost-effectiveness that
we have identified.
By mapping these data on figure 1, we see that the estimates
of Chew et al. [54] and Spencer et al. [13] imply a particularly
low CPLYG. The higher of the 2 estimates (i.e., that from Law
et al. [55]) illustrates a CPLYG of !Au$39,000, but the lower
estimate, for the period of 1983–1985, implies the opposite.
We assumed the rate of mother-to-child transmission of HIV,
without treatment, to be 28%. This was derived from an as-
sumption that the Australian population will breast-feed for at
least 6 months [56] and from the findings of a randomized trial
undertaken in Kenya [57] that reported a transmission rate of
28% at 6 months, among women enrolled in the breast-feeding
arm of the study. Although we might expect the Kenyan pop-
ulation to be quite different from that of a more developed
country, the transmission rate in the non-breast-feeding arm of
the Kenyan study was 20.5% and very close to the 20% trans-
mission rate reported for a non-breast-feeding group of women
in the United States [58]. We assumed a 2% rate of transmission
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Figure 1. Cost per life-year gained, for universal antenatal HIV screening in Australia, for all prevalences (range, 0%–0.02%)
when interventions were used, which, we suggest, may be a con-
servative estimate. The interventions we advocate in this model
may well achieve a lower rate, such as 1.2% (reported by Cooper
et al. [58]). In fact, there were zero transmissions in 103 babies
delivered to women in Australia who were aware of their HIV
status before birth, between 1998 and 2002 [7].
We assumed that 4% of pregnant women with confirmed
HIV infection would terminate the pregnancy. Although the
literature suggests that the figure might be as high as 20% [59],
this finding was derived from data obtained between 1990 and
1995, a time before the effectiveness of antiretroviral therapies
had been fully realized and when the risks of vertical trans-
mission were still considerable. The value that we used was
obtained from data obtained in 1999 and, we argue, is a more
accurate reflection of current practice.
There is debate among economists and policy makers over
whether the same or different discount rates should be applied
to costs and benefits that arise in the future [38–43]. In the
baseline analysis, we chose to discount future costs and benefits
at the same rate, and we evaluated scenarios where benefits
were not discounted at all. Of course, the less aggressively that
future benefits are discounted, the lower the prevalence atwhich
universal screening is cost-effective.
The estimated marginal cost of Au$4.50 (US$2.40)/screening
test exceeds estimates reported for the United Kingdom [1].
By pooling serum samples, English researchers found that costs
could be reduced to £0.60 (Au$1.60; US $0.86)/test, without
prejudicing test sensitivity or specificity.
There is great uncertainty with regard to the gain in life ex-
pectancy due to either an avoided case of HIV or the early
diagnosis of the mother and for the subsequent lifetime costs of
treating a child with HIV infection. For this analysis, we used
the best available sources and included scenarios that reflect a
wide range of values. Because treatments are evolving rapidly,
the likely survival and cost of achieving that survival are difficult
to predict. We recommend that further research that determines
values for this important variable be undertaken.
The present study has illustrated that universal antenatal
screening for HIV infection is cost-effective in a setting of very
low prevalence. Furthermore, there is some evidence that the
true prevalence in the currently unscreened antenatal popu-
lation of Australia would exceed the minimum required for
this intervention to be considered cost-effective.
The other published cost-effectiveness studies were con-
ducted in the United Kingdom [1, 5], where 75% of 300 births
to women with HIV are undetected each year [60]; the United
States [3], where the prevalence of undiagnosed HIV infection
in the general population is estimated to be at least 1% [61];
New Zealand [2], where the prevalence of HIV infection in
antenatal women is estimated to be 0.02%–0.04%; and Canada,
where the prevalence of HIV infection in antenatal women is
estimated to be 0.037% [4].
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Table 3. Results of sensitivity analysis—the lowest prevalence of HIV infection among the currently
unscreened antenatal population of Australia at which universal screening is cost-effective.
Variable
Value used in modela
Unfavorable Favorable
Patients who accept screening 0.0060 (1/16,667) 0.0042 (1/23,810)
Termination of pregnancy rates in HIV-positive women 0.0047 (1/21,277) 0.0043 (1/23,256)
Incidence of transmission without treatment 0.0058 (1/17,241) 0.0036 (1/27,778)
Incidence of transmission with treatment 0.0047 (1/21,277) 0.0041 (1/24,390)
Gain in life expectancy for case avoided 0.0075 (1/13,333) 0.0038 (1/26,316)
Gain in life expectancy due to early treatment for mother 0.0052 (1/19,231) 0.0039 (1/25,641)
Hours of pretest counselling 0.0099 (1/10,101) 0.0033 (1/30,303)
Discount rate for benefits 0.0071 (1/14,085) 0.0016 (1/62,500)
Unit cost of HIV antibody test 0.0079 (1/12,658) 0.0038 (1/26,316)
Investment in education for each HCP that may perform screening 0.0106 (1/9434) 0.0035 (1/28,571)
NOTE. Data are percentage (no. of cases/population). HCP, health-care professional (includes all midwives, general prac-
titioners, and obstetricians).
a With all other variables at baseline values.
One of the cost-effectiveness studies in the United Kingdom
[1] assumed a value of £10,000 (US$15,000)/life-year gained; the
authors recommended that universal screening be adopted under
most scenarios within London and outside London if uptake was
190% and if the cost of an HIV antibody test was Au$1.60
(US$0.86). The study of pregnant women in Chicago [3] valued
a life-year gained at US$50,000 and concluded that universal
antenatal HIV screening was cost-effective. The authors of the
New Zealand study [2] also concluded that universal antenatal
HIV screening should be adopted if policy makers are will-
ing to pay NZ$17,000 (US$8400)/life-year gained. The research
conducted in Canada estimated that the net savings attribut-
able to prevented infections among babies carried to term were
Can$166,000 (US$121,000), with a savings per prevented case of
Can$75,300 (US$55,000) [4].
The results of our research suggest that a policy of universal
screening remains cost-effective at much lower prevalences than
those assumed or reported for the Unites States, United King-
dom, Canada, and New Zealand. Universal screening should
therefore be considered in countries with the following char-
acteristics: very low prevalence, a relatively high per capita in-
come, an established infrastructure for prenatal care, and a
health-care system already delivering optimal risk-reducing
therapies and treatments.
Comparisons can also be drawn with other screening pro-
grams in Australia. The authors of a review of the effective-
ness of mammographic screening of women in Australia aged
40–49 concluded the CPLYG to lie between Au$24,000 and
Au$65,000 [62] (US$13,000–35,000). Also, an analysis of the
decisions made by the Australian Pharmaceutical LicensingAu-
thorities between 1991 and 1996 [63] indicated that policy
makers were unlikely to recommend a drug if the CPLYG was
1Au$86,000 (US$46,000) but most often endorsed a drug if
the CPLYG was !Au$48,000 (US$26,000); these costs are re-
ported in 2002 prices [64]. Clearly, the threshold of Au$39,000
(US $21,000)/life-year that we have used here compares fa-
vorably. Also, investing the additional Au$1.8 million (US$0.9
million) in universal screening would increase annual expen-
ditures on health care by just 0.003% [65].
As illustrated by the data in table 3, we found the results to
be highly sensitive to whether investments were made in the
continuing professional education of the health-care profes-
sionals who would counsel the women and offer the screening.
However, for all scenarios, we assumed that the uptake of
screening would remain at 95% and that informed consent
would be obtained in an ethical manner. The literature [45, 59,
66–75] suggests that high compliance and ethical screening is
determined by careful and sensitive pretest counselling, the level
of training for each health-care professional, a need to take
particular care when English is not the first language (in coun-
tries where English is the most commonly spoken language),
and the age, attitudes, and experience of the health-care pro-
fessionals. On the basis of this, we recommend that appropri-
ate investments be made in continuing professional education.
Note that universal screening was found to be acceptable to
pregnant women in New Zealand [76], Sweden [66], and Scot-
land [45] and that women with HIV who are unaware of their
status are more likely to accept screening if it is presented to
them as “routine,” rather than as something that they have
been “selected” for [71]. Also, after a change in the testing
policy at a London genito-urinary medicine clinic, where de-
tailed verbal counselling was replaced with a shorter written
explanation, a substantial increase of the proportion of clients
who accepted HIV screening was observed [77].
The results presented here reflect an average for the whole of
Australia. There may well be variation in the prevalence of HIV
infection and the intensity of the current screening activities
across the states and territories of Australia, and this will have
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implications for cost-effectiveness. The results would be made
more transparent if accurate statistics on the prevalence of HIV
infection for the antenatal population were obtained. However,
implementation of universal screening would, of course, quickly
generate these data.
In summary, and in response to the question posed in the
title of this paper, our research shows that, even at a very low
prevalence of unrecognized HIV among pregnant women in
Australia, universal antenatal screening for HIV would be a
cost-effective use of resources.
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